Can Low Dose Naltrexone (LDN) be taken indefinitely?
Long-term use of LDN: it's being taken for chronic conditions Do you need to stop it at some point?
To give you a long answer to that read, my article in Townsend Newsletter that will come out in either the June or July issue, that I just wrote on low dose naltrexone, and I listed every single disease that I know of it can be used in, which is a myriad of them. You can get on the LDN Research Trust website. So anything that's inflammatory. My latest disease process that I'm getting really good results in is Type 2 diabetes. It's an inflammatory disease, so I use it for all autoimmune diseases, any of my patients with cancer, and getting great results. Weight loss, anything that is inflammatory. Prevention of memory loss, treatment of memory loss - it's a game changer. As I said in the article in the Townsend Newsletter, this is my 44th year of practice.
It's rare when there is a single drug that is really a game changer, and in medicine, honestly, I have found two of them: low-dose naltrexone, and bioidentical hormones. In my 44 years of practice, I can't say enough about LDN. It is the world's best. I don't have any major disease processes. I'm a menopausal woman, but I am missing part of my gut because of the fact that I had a major problem when I delivered my first child. So because you can have inflammation in the gut, I do personally take 1 milligram of LDN every day. So there's a lot to be said for it. And I think lastly, can you say any more about long-term use: my patients stay on it forever. I honestly haven't taken anybody off of LDN, because I've been able to reduce side effects by reducing the dose.
A Question from the Low Dose Naltrexone (LDN) Q&A Webinar on COVID and Long Haulers, the 2-hour seminar is available along with an extensive 278 page PowerPoint PDF and a Treatment Protocol, https://www.ldnrtevents.com/collections/webinars-and-training-courses/products/LDN-covid-19-covid-long-haulers-webinar-dr-pamela-smith
Dr Pamela Smith, LDN Specialist and Advisor to the LDN Research Trust